SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 13, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Esophageal Squamous Cell Carcinomas
Interventions
DRUG

SI-B001

Administered by intravenous drip every 2 weeks (Q2W). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.

DRUG

Irinotecan

The dose of irinotecan was 180mg/m2 Q2W, the infusion method was according to the drug instructions, SI-B001 and irinotecan were used on the same day, and irinotecan was injected after SI-B001 infusion.

Trial Locations (6)

100142

Beijing Cancer Hostital, Beijing

Unknown

Anyang Cancer Hospital of Henan Province, Anyang

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang

Xuzhou Central Hospital, Xuzhou

Shanxi Cancer Hospital, Taiyuan

Suining Central Hospital, Suining

All Listed Sponsors
lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY